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DObjective:Although surgical aortic valve replacement (SAVR) is the treatment of choice for patients with aortic
valve stenosis, transcatheter aortic valve replacement (TAVR) and sutureless aortic valve replacement
(SU-AVR) have shown good results. The aim of our multicenter, propensity-matched study was to compare
the clinical and hemodynamic outcomes of surgical SAVR, transapical TAVR (TA-TAVR), and SU-AVR.
Methods: We analyzed data from 566 TA-TAVR, 349 SAVR, and 38 SU-AVR patients treated from January
2009 to March 2012. We used a propensity-matching strategy to compare on-pump (SAVR, SU-AVR) and
off-pump (TA-TAVR) surgical techniques. The outcomes were analyzed using multivariate weighted logistic
regression or multinomial logistic analysis.
Results: In the matched cohorts, the 30-day overall mortality was significantly lower after SAVR than TA-TAVR
(7% vs 1.8%, P ¼ .026), with no differences in mortality between SU-AVR and TA-TAVR. Multivariate
analysis showed SU-AVR to have a protective effect, although not statistically significant, against aortic
regurgitation, pacemaker implantation, and renal replacement therapy compared with TA-TAVR. Compared
with TA-TAVR, SAVR demonstrated significant protection against aortic regurgitation (odds ratio, 0.04;
P< .001) and a trend toward protection against death, pacemaker implantation, and myocardial infarction.
The mean transaortic gradient was 10.3  4.4 mm Hg, 11  3.4 mm Hg, and 16.5  5.8 mm Hg in the
TA-TAVR, SU-AVR, and SAVR patients, respectively.
Conclusions: SAVR was associated with lower 30-day mortality than TA-TAVR. SAVR was also associated
with a lower risk of postoperative aortic regurgitation compared with TA-TAVR.We did not find other significant
differences in outcomes among matched patients treated with SAVR, SU-AVR, and TA-TAVR. (J Thorac Car-
diovasc Surg 2013;146:1065-71)Surgical aortic valve replacement (SAVR) is the treatment of
choice in patients with severe symptomatic aortic valve ste-
nosis (SSAVS). The results of SAVR are reproducible and
well established, and its complications are known.1 Howev-
er, in the past few years, new alternative therapeutic strate-
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The Journal of Thoracic and Carexpectation and good initial results. Transcatheter aortic
valve replacement (TAVR) has been proposed as an alterna-
tive treatment of high-risk or inoperable patients with
SSAVS. To date, its clinical and hemodynamic results, re-
ported in both prospective studies and national registries,
have been good.2-5 More recently, sutureless aortic valve
replacement (SU-AVR) was developed with the aim of
reducing the aortic crossclamp times and facilitating
minimally invasive access.6 SU-AVR is particularly indi-
cated for patients with multiple comorbidities who would
benefit from reduced operative times. Surgeons currently
have a variety of methods for treating SSAVS, depending
on a patient’s risk stratification: SAVR for most patients,
TAVR for high-risk or inoperable patients, and SU-AVR
for medium- or high-risk operable patients. Our group
recently published a propensity-matched study comparing
transapical TAVR (TA-TAVR) and SU-AVR showing that,
in select patients, SU-AVR is as safe and effective as
TA-TAVR. SU-AVR was also associated with a lower inci-
dence of paravalvular leak.7 That report was presented at
theAmericanAssociation forThoracic Surgery 92ndAnnual
Meeting in 2012, and, during the conference discussion, thediovascular Surgery c Volume 146, Number 5 1065
Abbreviations and Acronyms
AR ¼ aortic regurgitation
OHS ¼ open-heart surgery
PARTNER ¼ Placement of Aortic Transcatheter
Valve
SAVR ¼ surgical aortic valve replacement
SSAVS ¼ severe symptomatic aortic valve
stenosis
SU-AVR ¼ sutureless aortic valve replacement
TA-TAVR ¼ transapical transcatheter aortic valve
replacement
TAVR ¼ transcatheter aortic valve replacement
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Dneed for a comparison with a third matched group that
included SAVR patients emerged. Therefore, we decided to
update our previous study, including SAVR into the
analysis.7 The aim of the present multicenter, propensity-
matched study was to compare the clinical and hemody-
namic outcomes of SAVR, TA-TAVR, and SU-AVR.METHODS
The ethics committees approved the present study, and patient informed
consent for data collection and treatment was always collected.
Transapical Aortic Valve Replacement
We reviewed the data from 566 patients enrolled in the Italian Registry
of Trans-Apical Aortic Valve Implantation from April 2008 through May
2011. The main indication for TA-TAVI was SSAVS (aortic valve
area,<0.8 cm2; mean transaortic gradient,>40 mm Hg) associated with
1 or more of the following: (1) porcelain aorta; (2) high surgical risk (logis-
tic Euroscore I,>20%; Society of Thoracic Surgeons mortality score,
>10%); and (3) other serious comorbidities, including severe pulmonary
disease, previous total chest irradiation, hostile chest, or severe liver dis-
ease. TA-TAVI procedures were usually performed with the patient under
general anesthesia, and the only implanted devices were the SAPIEN or
SAPIEN XT pericardial balloon expandable bioprosthesis (Edwards Life-
Sciences, Irvine, Calif). The absolute contraindications for TA-TAVI were
left ventricular aneurysm with or without thrombotic stratification and an
extremely poor left ventricular ejection fraction (<15%). More details
about the Italian Registry of Trans-Apical Aortic Valve Implantation
registry, participating centers and investigators, device characteristics,
sizing and surgical technique, postoperative medications, and data
collection and analysis have been previously reported.8
Sutureless Aortic Valve Replacement
We prospectively collected and analyzed the data from 38 patients who
had undergone isolated SU-AVR with the Perceval S bioprosthesis (Sorin
Biomedica Cardio, Saluggia, Italy) at 3 Italian centers from March to
September 2011. Details about that cohort of patients and the structural
and technical features of the Perceval sutureless bioprosthesis have been
described in our previous report.7 The indications for SU-AVR were as
follows: SSAVS (aortic valve area,<0.8 cm2; mean transaortic gradient,
>40 mm Hg) and a high surgical risk profile, including advanced age
(>75 years), comorbidities, and patient frailty. The exclusion criteria for
the use of a Perceval S valve were previous implantation of a valve pros-
thesis or annuloplasty ring not replaced by the sutureless bioprosthesis,1066 The Journal of Thoracic and Cardiovascular Surdouble or multiple valve surgery, aneurysmal dilatation (45 mm) or
dissection of the ascending aorta, active endocarditis, bicuspid aortic valve,
and recent (<90 days) myocardial infarction. SU-AVR was performed
through a full sternotomy, mini-sternotomy, and mini-right thoracotomy
in 23 (60.5%), 4 (10.5%), and 11 (29%) patients, respectively. Moderate
hypothermic (32C) cardiopulmonary bypass and transverse aortic
crossclamping were used in all patients. Cold-blood cardioplegia was
usually administered in an antegrade fashion. Retrograde cardioplegia
was used according to surgeon’s preferences and the type of approach.
The mean aortic crossclamp and cardiopulmonary bypass time was
44  17 and 69  44 minutes, respectively.
Because no guidelines, position statements, nor recommendations about
SU-AVR are available, the choice between TAVR and SU-AVR, especially
in high-risk elderly patients, was made by each surgeon individually
according to the patient’s preoperative characteristics and clinical
observation.
Surgical Aortic Valve Replacement
We retrospectively collected data from 349 consecutive patients who
had undergone isolated SAVR from January 2009 through December
2011 at the University of Padova. We collected data from SAVR patients
specifically for the present study using exactly the same data set and defi-
nitions used for the SU-AVR and TA-TAVR patients. Data were obtained
directly from an ad hoc review of the official hospital medical charts and
not from already existing databases. All SAVR procedures were performed
through full sternotomy, with moderate hypothermic cardiopulmonary
bypass. Cold-blood cardioplegia was usually administered in both an ante-
grade and a retrograde fashion. Prostheses were implanted with 2-0 braided
pledgeted horizontal mattress sutures (pledgets on the ventricular side).
Bioprostheses and mechanical prostheses were used in 332 (95.1%) and
17 (4.9%) patients, respectively. The mean aortic crossclamp and cardio-
pulmonary bypass time was 93  27 and 124  33 minutes, respectively.
The patients in all groups underwent clinical and echocardiographic
assessment at the study site before the procedure and at hospital discharge.
Echocardiographic measurements were done according to the current rec-
ommendations.9 Prosthetic aortic regurgitation (AR) was classified as none
or trace, mild (1þ/3þ), moderate (2þ/3þ), or severe (3þ/3þ) according to
recent recommendations.10
Risk Factors and Endpoints
The preoperative risk factors were defined according to the Euroscore I
classification,11 and the postoperative outcomes and endpoints were
defined according to the Valve Academic Research Consortium
definitions.12 The recently updated Valve Academic Research Consortium
2 definitions13 were not available at the data analysis. The patients were
classified as receiving TA-TAVR or ‘‘open-heart surgery’’ (OHS: SU-
AVR or SAVR). The database records 10 variables: age, gender, body
surface area, logistic Euroscore I, New York Heart Association functional
class, left ventricular ejection fraction, concomitant mitral valve disease,
chronic obstructive pulmonary disease, peripheral vascular disease, and
aortic valve area. The dependent variable was a categorical variable
comparing the results of the TAVR technique with those of the OHS
technique. Within OHS, we further analyzed the results of TA-TAVR
versus SU-AVR and TA-TAVR versus SAVR. Our primary study endpoints,
defined before analysis, were all-cause 30-day mortality, disabling
stroke, permanent pacemaker implantation, renal replacement therapy,
periprocedural acute myocardial infarction (within 72 hours after the index
procedure), AR at discharge (1þ/3þ), and the transaortic gradient at
discharge.Statistical Analysis
Statistical analysis was performed using Stata, version 12.1 (StataCorp,
College Station, Tex). The preoperative demographic risk-related variablesgery c November 2013
TABLE 1. Characteristics of patient cohorts before matching
Variable OHS (n ¼ 387)
TA-TAVR
(n ¼ 566) P value
Age (y) 72.7  10.1 80.6  6.8 <.001
BSA (m2) 1.8  0.2 1.7  0.2 <.001
Logistic Euroscore (%) 14.2  11.2 25.5  15 <.001
LVEF (%) 59.1  10.6 52.7  13.6 <.001
AVAi (cm2/m2) 0.51  0.1 0.55  0.2 .001
Male gender (%) 48.3 40.8 .02
NYHA class  3 (%) 33.1 83.4 <.001
PVD (%) 36.7 51.2 <.001
COPD (%) 20.9 35.7 <.001
MR (%) 9.6 9.2 .07
OHS, Open-heart surgery (sutureless and surgical aortic valve replacement);
TA-TAVR, transapical aortic valve replacement; BSA, body surface area; LVEF, left
ventricular ejection fraction; AVAi, aortic valve area index; NYHA, New York Hear
Association; PVD, peripheral vascular disease; COPD, chronic obstructive pulmo-
nary disease; MR, mitral regurgitation.
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tigated. Categorical variables are expressed as frequencies and were
compared using the Fisher exact and chi-square tests. Continuous variables
are expressed as the mean  standard deviation and were compared using
the unpaired t test.
Standardized differences were used to assess the degree of baseline var-
iable balance using a well-validated technique.14 We estimated the propen-
sity score of the treatment category based on our 10 variables using a logit
model and a default P value of .01. The balancing property was satisfied
stratifying 953 of the original patients in 17 blocks.15 Subsequently, a
1:1 match on the propensity score, without replacement, was performed us-
ing the psmatch2 procedure,16 with a conservative caliper width of 20% of
the standard deviation of the log of propensity score.17 A total of 286 pa-
tients were successfully matched (143 TA-TAVR and 143 OHS). The
psmatch2 common support option also retained 347 unmatched TAVR pa-
tients. In these patients, the matching weight was missing; therefore, we
calculated a weight proportional to the inverse of their inclusion probability
within their original stratification block. The statistical significance of the
results was robust to several different weight specifications. Comparisons
between groups were performed considering the matched nature of the pro-
pensity score-matched sample. In particular, the paired t test or Wilcoxon
signed rank test was used for continuous variables and the McNemar test
for binary (dichotomous) variables. A multivariable logistic analysis of
the odds ratio of mortality and morbidity was finally performed on the
633 patients in the common support region, adjusting for the SU-AVR
and SAVR technique, preoperative covariates, and propensity score. For
this purpose, a weighted logistic model, saturated with event-related vari-
ables and propensity score inclusion, was used.TABLE 2. Characteristics of patient cohorts after matching in
common support region
Variable OHS (n ¼ 143)
TA-TAVR
(n ¼ 490) P value
Age (y) 73.5  12.6 80.4  7 <.001
BSA (m2) 1.8  0.3 1.7  0.2 .001
Logistic Euroscore (%) 18.3  14.6 24.5  14.1 <.001
LVEF (%) 58.1  10.9 53.4  13.6 <.001
AVAi (cm2/m2) 0.55  0.2 0.54  0.2 .93
Male gender (%) 49.7 40.8 .07
NYHA (%) 54.5 81.2 <.001
PVD (%) 37.1 48.8 .17
COPD (%) 25.9 33.9 .08
MR (%) 24.5 68.2 <.001
OHS, Open-heart surgery (sutureless and surgical aortic valve replacement);
TA-TAVR, transapical aortic valve replacement; BSA, body surface area; LVEF, left
ventricular ejection fraction; AVAi, aortic valve area index; NYHA, New York Hear
Association; PVD, peripheral vascular disease; COPD, chronic obstructive pulmo-
nary disease; MR, mitral regurgitation.RESULTS
A total of 286 patients were successfully matched: 143
underwent TA-TAVR and 143 underwent OHS. Also, 633
patients were included in the common support region of
the propensity analysis. The preoperative clinical character-
istics of the patients in the OHS and TA-TAVR cohorts are
listed in Tables 1 through 3, which listed the unmatched
cohorts, the cohorts after matching in the common
support region, and the cohorts after caliper matching,
respectively. In the unmatched cohort (Table 1), the
TA-TAVR patients were older (80.6  6.8 vs 72.7  10.1
years; P< .001) and had a significantly greater logistic
Euroscore (25.5%  15% vs 14.2%  11.2%;
P< .001). The TA-TAVR patients also had a worse New
York Heart Association functional class and were more
likely to have peripheral vascular disease (51.2% vs
36.7%; P < .001) and chronic obstructive pulmonary
disease (35.7% vs 20.9%; P< .001). After matching the
2 cohorts, they were similar in terms of body surface area,
logistic Euroscore left ventricular ejection fraction,
peripheral vascular disease, and chronic obstructive
pulmonary disease. Even after matching, age continued to
be significantly different among the cohorts. However,
because age is an important component of the logistic
Euroscore we were confident that multivariate logistic
regression adjusted for this residual imbalance in the
observed baseline covariates. Table 4 lists the study
endpoints in the 633 patients matched in the common sup-
port region. The 30-day overall mortality was significantlyThe Journal of Thoracic and Carlower in the SAVR than in TA-TAVR group (8.6% vs 0.9%,
P ¼ .002), and no difference was found between the
SU-AVR and TA-TAVR groups regarding mortality. The
causes of death in the TA-TAVR patients were multiorgan
failure in 15 patients (35.7%), sepsis in 10 patients
(23.8%), arrhythmias in 6 patients (14.3%), renal
insufficiency in 2 patients (4.8%), severe hemorrhage in 6
patients (14.3%), and mesenteric ischemia in 3 patients
(7.1%). One patient died in the SAVR matched group of
multiorgan failure. No deaths were observed in the
SU-AVR matched cohort. The TA-TAVR group had
significantly lower transaortic gradients than the SAVR
group (10.3  4.4 mm Hg vs 16.5  5.8 mm Hg,
P<.001), but they had a greater incidence of at least mild
(1þ/3þ) AR (34.1% vs 1.8%; P< .001). Furthermore,
the SAVR group had a lower incidence of postoperative
pacemaker implantation (0.9% vs 6.1%; P ¼ .018) anddiovascular Surgery c Volume 146, Number 5 1067
TABLE 3. Characteristics of patient cohorts after caliper 1:1
matching
Variable OHS (n ¼ 143)
TA-TAVR
(n ¼ 143) P value
Age (y) 73.5  12.6 77.6  9 .003
BSA (m2) 1.8  0.3 1.7  0.2 .12
Logistic Euroscore (%) 18.3  14.6 20.2  12.5 .22
LVEF (%) 58.1  10.9 56.1  13 .15
AVAi (cm2/m2) 0.55  0.2 0.55  0.2 .93
Male gender (%) 49.7 37.1 .03
NYHA (%) 54.5 65 .08
PVD (%) 37.1 42.7 .43
COPD (%) 25.9 32.2 .25
MR (%) 24.5 32.9 .06
OHS, Open-heart surgery (sutureless and surgical aortic valve replacement);
TA-TAVR, transapical aortic valve replacement; BSA, body surface area; LVEF, left
ventricular ejection fraction; AVAi, aortic valve area index; NYHA, New York Hear
Association; PVD, peripheral vascular disease; COPD, chronic obstructive pulmo-
nary disease; MR, mitral regurgitation.
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P ¼ .001). No other endpoints were significantly different
statistically between the TA-TAVR and SAVR or between
the TA-TAVR and SU-AVR groups. The analysis of
endpoints in the 286 caliper 1:1 matched patients is listed
in Table 5. A difference was still found in mortality between
the TA-TAVR and SAVR groups, although the statistical
significance was less pronounced than with the analysis of
the common support region (7% vs 1.8%; P ¼ .026).
Also, in the 1:1 matched cohort, TA-TAVR demonstrated
significantly lower gradients than SAVR (10.7  4.4 mm
Hg vs 16.5 5.8 mm Hg; P<.001) and a greater incidence
of AR (28.7% vs 1.8%; P<.001). Themultivariate analysis
showed that SU-AVR had a protective effect, although the
difference was not statistically significant, against AR,
pacemaker implantation, and renal replacement therapy
compared with TA-TAVR. However, compared with
TA-TAVR, SAVR demonstrated significant protection
against AR (odds ratio, 0.04; P<.001) and a trend toward
protection against death, pacemaker implantation, and
myocardial infarction. The effect of SAVR and SU-AVRTABLE 4. Postoperative outcomes after TA-TAVR, SU-AVR, and SAVR; a
Outcome TA-TAVR (n ¼ 490) SU-AVR (n ¼ 31
Death (n) 42 (8.6) 0
Stroke (n) 12 (2.5) 0
PPM (n) 30 (6.1) 1 (3.2)
RRT (n) 37 (7.6) 1 (3.2)
AMI (n) 9 (1.9) 0
Postoperative AR (1þ/3þ) (n) 167 (34.1) 6 (19.4)
Mean gradient (mm Hg) 10.3  4.4 11.1  3.4
Data in parentheses are percentages. TA-TAVR, Transcatheter aortic valve replacement; SU
PPM, permanent pacemaker replacement; RRT, renal replacement therapy; AMI, acute myo
test.
1068 The Journal of Thoracic and Cardiovascular Suron the predefined endpoints, with respect to TA-TAVR, is
presented in Table 6.
DISCUSSION
The complete portfolio of aortic valve substitutes in-
cludes SAVR, SU-AVR, and TAVR. The present study is
the first to evaluate and compare, with a propensity-
matched analysis, the results of all these techniques in
patients with SSAVS. Although our study should be consid-
ered a preliminary study, it gives some important insights
into this contemporary and controversial issue. The main
findings of the present study were that SU-AVR and
SAVR might potentially have some advantages over
TAVR in selected patients. This could have resulted from
the patient selection process that occurred in our analysis.
The attempt to match these 3 cohorts resulted in selecting
the ‘‘worse’’ OHS patients and the ‘‘best’’ TAVR patients.
This was clearly shown in Tables 1 through 3, in which
the matched TA-TAVR cohort had fewer comorbidities
and lower logistic Euroscore values than the unmatched
cohort, and the matched SAVR patients had more comor-
bidities and greater logistic Euroscore values than the
unmatched cohort. Thus, as stated in our previous report,
these patients belong to a ‘‘gray zone,’’ in which an overlap
of indications is present for the different procedures.
However, even if the 3 groups after matching were similar
(especially after 1:1 caliper matching), other factors that
could have had a significant effect on patient outcomes,
such as frailty, were not considered. It is likely that this
-subgroup of patients, who belong to the ‘‘gray zone’’ of
surgical risk, were assigned to 1 or the other treatment group
on the basis of these unaccounted for conditions. The
empiric proportions in Tables 4 and 5 show that the
SAVR group had a significantly lower rate of death than
did the TA-TAVR group in the matched patients. This seems
to be in contrast to the results from the Placement of Aortic
Transcatheter Valve (PARTNER) trial3 but can be explained
by several reasons. The PARTNER trial was a prospective
randomized trial with strict inclusion and exclusion criteria
and was conducted in select centers that considered bothnalysis included 633 patients of common support region
) SAVR (n ¼ 112)
P value
TA-TAVR vs SU-AVR TA-TAVR vs SAVR
1 (0.9) .16 .002*
0 1 .14*
1 (0.9) 1 .018*
0 .72 .001*
1 (0.9) 1 .70*
2 (1.8) .12 <.001*
16.5  5.8 .36* <.001y
-AVR, sutureless aortic valve replacement; SAVR, surgical aortic valve replacement;
cardial infarction; AR, aortic regurgitation. *Two-tailed Fisher exact test. yUnpaired t
gery c November 2013
TABLE 5. Postoperative outcomes after TA-TAVR, SU-AVR, and SAVR; analysis included 286 patients with caliper matching 1:1
Outcome TA-TAVR (n ¼ 143) SU-AVR (n ¼ 31) SAVR (n ¼ 112)
P value
TA-TAVR vs SU-AVR TA-TAVR vs SAVR
Death (n) 10 (7) 0 1 (1.8) 0.21 .026*
Stroke (n) 4 (2.8) 0 0 1 .13*
PPM (n) 7 (4.9) 1 (3.2) 1 (0.9) 1 .082*
RRT (n) 7 (4.9) 1 (3.2) 0 1 .019*
AMI (n) 5 (3.5) 0 1 (0.9) 0.59 .23*
Postoperative AR (1þ/3þ) 41 (28.7) 6 (19.4) 2 (1.8) 0.37 <.001*
Mean gradient (mm Hg) 10.7  4.4 11.1  3.3 16.5  5.8 0.69* <.001y
Data in parentheses are percentages. TA-TAVR, Transcatheter aortic valve replacement; SU-AVR, sutureless aortic valve replacement; SAVR, surgical aortic valve
replacement; PPM, permanent pacemaker replacement; RRT, renal replacement therapy; AMI, acute myocardial infarction; AR, aortic regurgitation. *Two-tailed Fisher exact
test. yUnpaired t test.
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was based on the analysis of data from patients who had
undergone surgery in the ‘‘real world.’’ We only considered
TA-TAVR and not transfemoral TAVR. Furthermore, the
patient characteristics were different from those in the
PARTNER trial; in particular, the logistic Euroscore of
the PARTNER SAVR patients was 29%, but in our study,
it was 18% (also including the SU-AVR patients), and
this could explain the different 30-day mortality rate
between these 2 studies (PARTNER, 6.5%; our study,
0.9%). However, the power of the test in the 1:1 match
was 46%, and on multivariate analysis, TA-TAVR was
not found to be an independent predictor of mortality;
thus, this result should be interpreted with caution.
Even if the rate of AR in the SU-AVR patients seems high
(19%), one should consider that all the leaks were mild
(1þ/3þ), that this incidence was similar to that in other
series,18 and that these results were from surgeons’ early
experience using this new technique, with learning curve-
related issues. On multivariate analysis, SU-AVR seemed
to reduce the risk of postoperative AR, permanent pace-
maker implantation, and renal replacement therapy




TA-TAVR OR P value*
SAVR vs
TA-TAVR OR P value*
Death 1.00 — 0.23 .17
Postoperative
AR (1þ/3þ)
0.55 .23 0.04 <.001
Stroke 1.00 — 1.00 —
PM implantation 0.51 .53 0.97 .14
RRT 0.61 .68 1.00 —
AMI 1.00 — 0.38 .47
Mean gradient
at discharge
1.02 .56 1.19 <.001
OR, Odds ratio; TA-TAVR, transcatheter aortic valve replacement; SU-AVR, sutureless
aortic valve replacement; SAVR, surgical aortic valve replacement; PPM, permanent
pacemaker replacement; RRT, renal replacement therapy; AMI, acute myocardial
infarction; AR, aortic regurgitation. *Multivariate adjusted, logistic Z test.
The Journal of Thoracic and Carsignificant difference was in the reduction of AR in the
SAVR patients compared with that in the TA-TAVR
patients. Postoperative AR is a highly debated issue,
especially after the results of the PARTNER trial at
2 years showed that even a mild degree of AR significantly
worsens patient survival.19 The reason for an AR reduction
after SU-AVR was mainly because of the ‘‘open heart’’
implantation of sutureless valves, which enabled the
surgeon to remove valve leaflets and annular calcifications
and to directly measure the aortic annulus to choose
the most appropriate prosthesis size. Furthermore, the
prosthesis is implanted under direct vision; thus, if the final
result is not satisfactory, the valve can be removed and
repositioned either during the same aortic clamping or
with a second aortic clamping if the leak is discovered using
intraoperative transesophageal echocardiography.20 The
presence and distribution of calcium within the aortic
annulus has been demonstrated to predict AR after
TAVR21; thus, its removal could have an affect on reducing
postoperative AR after SAVR. All these mechanisms also
explain the advantage of SAVR over TAVR in the reduction
of the risk of AR. Postoperative AR is still a major issue that
must be solved before TAVR indications can be expanded
toward a lower risk patient population. Another important
issue related to TAVR is the rate of postoperative permanent
pacemaker implantation. Although self-expandable devices
were associated with a significantly greater incidence of
pacemaker implantation than balloon-expandable valves,22
a significant advantage was still found for ‘‘open-heart’’
devices compared with TAVR. The ‘‘blind’’ lateral
displacement of aortic annulus calcifications that occurs
during TAVR (during both balloon aortic valvuloplasty
and valve deployment), rather than their ‘‘surgical’’
removal, such as is usually performed in SU-AVR and
SAVR, could explain the greater incidence of conduction
tissue injuries. We also found that TA-TAVR patients
had significantly lower gradients than those receiving
‘‘open-heart’’ devices. The hemodynamic behavior of
transcatheter valves was therefore better than that of
conventional aortic prostheses. However, future largerdiovascular Surgery c Volume 146, Number 5 1069
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whether these differences have a significant clinical effect.
With the present study, we wish to highlight that surgical
aortic valve replacement is still the best choice for patients
with aortic valve stenosis. However, new therapeutic
options such as TAVR and SU-AVR can provide good
results in select patients. A center that is able to offer their
patients all these therapeutic alternatives can select the most
appropriate technique, tailoring the choice to each patient
and considering all crucial characteristics such as age,
comorbidities, frailty, and anatomy. A particularly careful
evaluation is needed for patients in the ‘‘gray zone,’’ who
can benefit from either technique. An experienced ‘‘aortic
team’’ will be able to make the most appropriate choice.
The limitations of the present study were mainly related
to the retrospective nature, the different procedures
conducted at different centers, the inclusion of TA-
TAVR–only patients, and the small number of patients in
the SU-AVR cohort.
In conclusion, our data have shown that no main differ-
ences exist in the outcomes among SAVR, TA-TAVR, and
SU-AVR. SAVRwas associated with a significant reduction
in postoperative AR compared with TA-TAVR. The latter,
however, showed lower transaortic gradients. A trend was
seen toward less AR in the SU-AVR group than in the
TA-TAVR group; however, this difference was not statisti-
cally significant. Future, larger, and, possibly, prospective
studies are needed to confirm our preliminary results.
The authors are grateful to Leila Hosseinian, MD, and Gianluca
Torregrossa, MD, for their kind and precious assistance in lan-
guage editing and manuscript revision.References
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Dr Martin Misfeld (Leipzig, Germany). I would like to thank
the American Association for Thoracic Surgery (AATS) for the
opportunity to discuss the report by Dr D’Onofrio and colleagues
and Dr D’Onofrio for supplying me with the report in a timely
manner.
The present study is a comparison of 566 patients undergoing
TA-TAVR in 20 Italian cardiac surgery centers and 38 patients
undergoing SAVR in 3 centers and 349 patients undergoinggery c November 2013
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Dconventional aortic valve replacement in 1 center. It represents
an extension of a study presented at last year’s AATS
meeting and has recently been published in the Journal of
Thoracic and Cardiovascular Surgery, in which comparisons
were made between patients receiving a transapical Edwards
SAPIEN valve and those who underwent implantation of the
Perceval S sutureless valve. To the best of my knowledge, the
present report is the first to compare these 3 patient groups
simultaneously.
Dr D’Onofrio and colleagues have used sophisticated pro-
pensity score matching to compare these 3 groups. However, the
overlapping treatment period of the 3 patient groups and the lack
of randomization very likely resulted in significant differences
among the groups. The patient factors that were not measured,
such as frailty, porcelain aorta, or other risk factors for conven-
tional surgery, were undoubtedly different among the groups.
Although these unmeasured patient factors could explain the
elevated mortality observed in the TAVR group, they are less likely
to have affected the observed hemodynamic differences among the
groups (ie, the lower transvalvular gradient and greater incidence
of AR in the TAVR group).
I have 4 questions for the authors.
First, what were the criteria for deciding whether patients
underwent TA-TAVR or sutureless valve implantation in the
elderly high-risk subgroup and what patient-related features would
have made you decide that 1 technique would be definitely more
suitable than the other?
Second, the paravalvular leak rate for the sutureless group was
greater than that usually mentioned in published studies. Do you
have an explanation for this?
Third, did the sutureless valve patients have lower crossclamp
and cardiopulmonary bypass times than those undergoing
conventional AVR?
Finally, is it time for a randomization trial between sutureless
valves and TAVR?The Journal of Thoracic and CarOnce again, I would like to thank the Association for the honor
of being able to discuss this unique and important study.
Dr D’Onofrio. Thank you for your kind comments and
questions.
Talking about your first question, actually, each of these tech-
niques has pros and cons for high-risk patients. I’m talking about
transcatheter and sutureless aortic valve replacement.
Transcatheter is, of course, less invasive. It can be performed on
the awake patient, especially if performed through transfemoral
access, and does not require cardiopulmonary bypass or aortic
crossclamping; thus, it is definitely less invasive. However, the
rate of paravalvular leak is still high.
In contrast, SAVR requires cardiopulmonary bypass and aortic
crossclamping. With this technique, the hemodynamic results in
terms of paravalvular leakage have been much better.
I think that the choice between these 2 alternative techniques
should be tailored to the characteristics of each patient,
considering age, comorbidities, and, as you mentioned, frailty
and other factors that usually are not included in risk scores.
Regarding the incidence of paravalvular leak, it was high in the
sutureless group, that is true, but evenmildARwas included in these
analyses. The patients with mild AR were actually the first 30 pa-
tients who received the sutureless valve in our country. It was at
the very beginning of the learning curve. Currently, we have been
observing a progressive decrease in paravalvular leakage as our
experience in sizing and the implantation technique has improved.
The crossclamp and cardiopulmonary bypass time was
44 minutes and 69 minutes, respectively, in the sutureless group.
Again, this was the very beginning of our experience, and we
now are observing that the crossclamp time in these patients can
be as low as 20 minutes with the improvement in experience.
Of course, a trial would be an excellent idea. However, as you
mentioned, these are 3 techniques for 3 different groups of
patients. Thus, it would not be easy to design a prospective study
to include all 3 techniques in similar patients.diovascular Surgery c Volume 146, Number 5 1071
